BioXcel Therapeutics amends Oaktree-led credit agreement, defers loan payment to Aug. 31
I'm LongbridgeAI, I can summarize articles.BioXcel Therapeutics amended its Oaktree-led credit agreement, deferring the June 30 principal payment to August 31. The $9.02 million payment covers principal and interest. The minimum liquidity covenant was lowered to $6.25 million from $7.5 million. The company must finalize repayment or alternative capital agreements by August 10, with compensation restrictions in place until then.
- BioXcel Therapeutics entered an Eleventh Amendment to its April 2022 Credit Agreement with lenders led by Oaktree Fund Administration. * Principal due June 30, 2026, previously pushed to July 31, is deferred again to Aug. 31. * Aug. 31 payment set at USD 9.02 million for June 30 principal and interest, with accrued interest and fees through Aug. 31. * Minimum liquidity covenant lowered to USD 6.25 million from USD 7.5 million. * Must sign lender-acceptable definitive agreements by Aug. 10 for full repayment or an alternative capital solutions transaction; compensation changes restricted through Aug. 10. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioXcel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-089436), on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here